(Q33943388)

English

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

0 references

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor (English)

1 reference

Europe PubMed Central

30 July 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

4

object named as

Jaap Verweij

1 reference

Europe PubMed Central

30 July 2017

author name string

Paul Hamberg

1

1 reference

Europe PubMed Central

30 July 2017

Margaret M Woo

2

1 reference

Europe PubMed Central

30 July 2017

Lin-Chi Chen

3

1 reference

Europe PubMed Central

30 July 2017

Maria Grazia Porro

5

1 reference

Europe PubMed Central

30 July 2017

Lily Zhao

6

1 reference

Europe PubMed Central

30 July 2017

Wenkui Li

7

1 reference

Europe PubMed Central

30 July 2017

Diane van der Biessen

8

1 reference

Europe PubMed Central

30 July 2017

Sunil Sharma

9

1 reference

Europe PubMed Central

30 July 2017

Thomas Hengelage

10

1 reference

Europe PubMed Central

30 July 2017

Maja de Jonge

11

1 reference

Europe PubMed Central

30 July 2017

publication date

26 June 2011

1 reference

Europe PubMed Central

30 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

30 July 2017

68

1 reference

Europe PubMed Central

30 July 2017

3

1 reference

Europe PubMed Central

30 July 2017

805-813

1 reference

Europe PubMed Central

30 July 2017

https://scigraph.springernature.com/pub.10.1007/s00280-011-1693-x

0 references

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

HDAC family: What are the cancer relevant targets?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

A Multiple Testing Procedure for Clinical Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3162150

28 July 2018

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1693-X

21 January 2018

Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1693-X

21 January 2018

Clinical Toxicities of Histone Deacetylase Inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1693-X

21 January 2018

Identifiers

10.1007/S00280-011-1693-X

1 reference

Europe PubMed Central

30 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33943388&oldid=1955473359"